GDNF and Abnormal retinal morphology: Given the encouraging preclinical outcomes with hNPCGDNF shown here, as well as long-term safety of CNS10-NPC-GDNF in the ALS spinal cord, this cell product holds great promise as a therapeutic option for RP and other retinal diseases.